LOQUS23 THERAPEUTICS: Funding, Investors & Team (Sep 2026)
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
LOQUS23 THERAPEUTICS has raised $46.5M across 1 funding round on record, the most recent a Series A of $46.5M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
LOQUS23 THERAPEUTICS Company Profile and Key Stats
Latest funding round on record: Oct 2024.
LOQUS23 THERAPEUTICS Funding Rounds
LOQUS23 THERAPEUTICS Founders and Leadership Team
Contact details for the LOQUS23 THERAPEUTICS team: 1 of 1 has an email address on file.
Start 14-day free trial →LOQUS23 THERAPEUTICS Funding Compared to Other Biotechnology Startups
LOQUS23 THERAPEUTICS' latest round of $46.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like LOQUS23 THERAPEUTICS in Biotechnology and London
Companies Similar to LOQUS23 THERAPEUTICS
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
LOQUS23 THERAPEUTICS Funding FAQs
What does LOQUS23 THERAPEUTICS do?
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
How much funding has LOQUS23 THERAPEUTICS raised?
LOQUS23 THERAPEUTICS has raised $46.5M across 1 round on record. The most recent is a Series A of $46.5M announced in Oct 2024.
When did LOQUS23 THERAPEUTICS last raise funding?
LOQUS23 THERAPEUTICS' most recent funding round on record is a Series A of $46.5M, announced in Oct 2024.
Who founded LOQUS23 THERAPEUTICS?
FundedIQ lists David Reynolds (Founder) at LOQUS23 THERAPEUTICS.
Where is LOQUS23 THERAPEUTICS headquartered?
LOQUS23 THERAPEUTICS is based in London, England, United Kingdom.
How many employees does LOQUS23 THERAPEUTICS have?
LOQUS23 THERAPEUTICS is in the 1-10 employee band.
How does LOQUS23 THERAPEUTICS' funding compare to other Biotechnology startups?
LOQUS23 THERAPEUTICS' latest round of $46.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's LOQUS23 THERAPEUTICS Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for LOQUS23 THERAPEUTICS is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.